Nothing Special   »   [go: up one dir, main page]

AR062741A1 - Metodo para aumentar la hidratacion de la mucosa y la evacuacion de l a mucosa mediante tratamiento con bloquadores de los canales del sodio y osmolitos - Google Patents

Metodo para aumentar la hidratacion de la mucosa y la evacuacion de l a mucosa mediante tratamiento con bloquadores de los canales del sodio y osmolitos

Info

Publication number
AR062741A1
AR062741A1 ARP070103971A ARP070103971A AR062741A1 AR 062741 A1 AR062741 A1 AR 062741A1 AR P070103971 A ARP070103971 A AR P070103971A AR P070103971 A ARP070103971 A AR P070103971A AR 062741 A1 AR062741 A1 AR 062741A1
Authority
AR
Argentina
Prior art keywords
chor8
independently
nr7r10
ch2or8
ch2ch2o
Prior art date
Application number
ARP070103971A
Other languages
English (en)
Original Assignee
Hirsh Andrew J
Boucher Richard C
Johnson Michael R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hirsh Andrew J, Boucher Richard C, Johnson Michael R filed Critical Hirsh Andrew J
Publication of AR062741A1 publication Critical patent/AR062741A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Métodos y composiciones para tratar enfermedades mejoradas por una mayor depuracion mucociliar e hidratacion de la mucosa administrando una cantidad eficaz de un bloqueador de los canales de sodio segun lo definido en la presente y un osmolito a un sujeto que necesita una mayor depuracion mucociliar e hidratacion de la mucosa. Reivindicacion 14: Una composicion que comprende (a) un bloqueador de los canales de sodio representado por la formula (1) en la cual X es H, halogeno, trifluormetilo, alquilo inferior, fenilo sin sustituir o sustituido, alquilo inferior-tio, fenil-alquilo inferior-tio, alquilo inferior-sulfonilo, o fenil-alquilo inferior-sulfonilo; Y es H, hidroxilo, mercapto, alcoxi inferior, alquilo inferior-tio, halogeno, alquilo inferior, arilo mononuclear sin sustituir o sustituido, o -N(R2)2; R1 es H o alquilo inferior; cada R2 es, independientemente, -R7, -(CH2)m-OR8, -(CH2)m-NR7R10, -(CH2)n(CHOR8)(CHOR8)n-CH2OR8, -(CH2CH2O)m-R8, -(CH2CH2O)m-CH2CH2NR7R10, -(CH2)n- C(=O)NR7R10, -(CH2)n-Zg-R7, -(CH2)m-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -(CH2)n-CO2R7, o como en formula (2); R3 y R4 son en forma individual e independientemente, H, un grupo representado por la formula (3), alquilo inferior, hidroxi alquilo inferior, fenilo, fenilalquilo inferior, (halofenil)-alquilo inferior, (alquilfenilalquilo)-inferior, (alcoxifenilo)inferior-alquilo inferior, naftil-alquilo inferior, o piridil-alquilo inferior, con la condicion de que por lo menos uno de R3 y R4 es un grupo representado por la formula (3) en la cual cada RL es, independientemente -R7, -(CH2)n-OR8, -O-(CH2)m-OR8, -(CH2)n-NR7R10, -O-(CH2)m-NR7R10, (CH2)n(CHOR8)(CHOR8)n-CH2OR8, -O-(CH2)m(CHOR8)(CHOR8)n-CH2OR8, -(CH2CH2O)m-R8, -O-(CH2CH2O)m-R8, -(CH2CH2O)m- CH2CH2NR7R10, -O-(CH2CH2O)m-CH2CH2NR7R10, -(CH2)n-C(=O)NR7R10, -O-(CH2)m-C(=O)NR7R10, -(CH2)n-(Z)g-R7, -O-(CH2)m-(Z)g-R7, -(CH2)n-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -O-(CH2)m-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -(CH2)n-CO2R7, -O-(CH2)m-CO2R7, -OSO3H, -O- glucuronido, -O-glucosa, formulas (4) o (2), cada o es, independientemente, un numero entero del 0 al 10; cada p es un numero entero del 0 al 10; con la condicion de que la suma de o y p en cada cadena contigua sea del 1 al 10; cada x es, independientemente, O, NR10, C(=O), CHOH, C(=N-R10), CHNR7R10, o representa un enlace simple; cada R5 es, independientemente, -(CH2)m-OR8, -O-(CH2)m-OR8, -(CH2)n-NR7R10, -O-(CH2)m-NR7R10, (CH2)n(CHOR8)(CHOR8)n-CH2OR8, -O-(CH2)m(CHOR8)(CHOR8)n- CH2OR8, -(CH2CH2O)m-R8, -O-(CH2CH2O)m-R8, -(CH2CH2O)m-CH2CH2NR7R10, -O-(CH2CH2O)m-CH2CH2NR7R10, -(CH2)n-C(=O)NR7R10, -O-(CH2)m-C(=O)NR7R10, -(CH2)n-(Z)g-R7, -O-(CH2)m-(Z)g-R7, -(CH2)n-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -O-(CH2)m-NR10-CH2(CHOR8)(CHOR8)n- CH2OR8, -(CH2)n-CO2R7, -O-(CH2)m-CO2R7, -OSO3H, -O-glucuronido, -O-glucosa, formulas (4), (2),o (5); cada R6 es, independientemente -R7, -OR11, -N(R7)2, -(CH2)m-OR8, -O-(CH2)m-OR8, -(CH2)n-NR7R10, -O-(CH2)m-NR7R10, (CH2)n(CHOR8)(CHOR8)n-CH2OR8, -O- (CH2)m(CHOR8)(CHOR8)n-CH2OR8, -(CH2CH2O)m-R8, -O-(CH2CH2O)m-R8, -(CH2CH2O)m-CH2CH2NR7R10, -O-(CH2CH2O)m-CH2CH2NR7R10, -(CH2)n-C(=O)NR7R10, -O-(CH2)m-C(=O)NR7R10, -(CH2)n-(Z)g-R7, -O-(CH2)m-(Z)g-R7, -(CH2)n-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -O-(CH2)m- NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -(CH2)n-CO2R7, -O-(CH2)m-CO2R7, -OSO3H, -O-glucuronido, -O-glucosa, formulas (4) o (2), en la cual cuando dos R6 son -OR11 y están ubicados en forma adyacente entre sí en un anillo de fenilo, las porciones alquilo de los dos R6 pueden estar enlazadas entre sí para formar un grupo metilendioxi, cada R7 es, independientemente, H o alquilo inferior; cada R8 es, independientemente, H, alquilo inferior, -C(=O)-R11, glucuronido, 2-tetrahidropiranilo, o formula (5); cada R9 es, independientemente -CO2R7, -CON(R7)2, -SO2CH3, o -C(=O)R7; cada R10 es, independientemente, H, -SO2CH3, -CO2R7, -C(=O)NR7R9, -C(=O)R7, o -CH2-(CHOH)n-CH2OH; cada Z es, independientemente, CHOH, C(=O), CHNR7R10, C=NR10, o NR10; cada R11 es, independientemente, alquilo inferior; cada g es, independientemente, un numero entero del 1 al 6; cada m es, independientemente, un numero entero del 1 al 7; cada n es, independientemente, un numero entero del 0 al 7; cada Q es, independientemente, C-R5, C-R6, o un átomo de N, donde como mucho tres Q en un anillo son átomos de N y por lo menos una Q es C-R5; o su sal farmacéuticamente aceptable, incluyendo a todos los enantiomeros, diastereomeros y mezclas racémicas de los mismos; y (b) un compuesto osmoticamente activo. Reivindicacion 17: La composicion de acuerdo con la reivindicacion 14, donde el bloqueador de los canales de sodio representado por la formula (1) es como en el grupo de formulas (6).
ARP070103971A 2006-09-07 2007-09-07 Metodo para aumentar la hidratacion de la mucosa y la evacuacion de l a mucosa mediante tratamiento con bloquadores de los canales del sodio y osmolitos AR062741A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84266906P 2006-09-07 2006-09-07
US84517106P 2006-09-18 2006-09-18

Publications (1)

Publication Number Publication Date
AR062741A1 true AR062741A1 (es) 2008-12-03

Family

ID=39158091

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103971A AR062741A1 (es) 2006-09-07 2007-09-07 Metodo para aumentar la hidratacion de la mucosa y la evacuacion de l a mucosa mediante tratamiento con bloquadores de los canales del sodio y osmolitos

Country Status (12)

Country Link
US (1) US8058278B2 (es)
EP (1) EP2059237A4 (es)
JP (1) JP2010502738A (es)
KR (1) KR20090065508A (es)
AR (1) AR062741A1 (es)
AU (1) AU2007294547A1 (es)
BR (1) BRPI0716884A2 (es)
CA (1) CA2663041A1 (es)
EA (1) EA200970258A1 (es)
MX (1) MX2009002602A (es)
TW (1) TW200817343A (es)
WO (1) WO2008031028A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
CN1758930B (zh) 2003-03-27 2010-06-09 株式会社新日本科学 鼻腔用粉末药剂喷药装置
KR20060060027A (ko) * 2003-08-18 2006-06-02 패리온 사이언스 인코퍼레이티드 캡핑된 피라지노일구아니딘 나트륨 채널 차단제
JP4922762B2 (ja) 2004-08-10 2012-04-25 株式会社新日本科学 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US7399766B2 (en) * 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
PT2035004E (pt) * 2006-06-09 2012-11-21 Parion Sciences Inc Bloqueadores dos canais de sódio de pirazinoilguanidona substituída com fenilo que possuem actividade agonista beta
US8324218B2 (en) * 2006-06-09 2012-12-04 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
AR062742A1 (es) * 2006-09-07 2008-12-03 Johnson Michael R Hidratacion de la mucosa y depuracion de la mucosa aumentadas por tratamiento con bloquadores de canales de sodio y osmolitos
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
WO2008124491A1 (en) * 2007-04-03 2008-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use taste modulators
US20080293740A1 (en) * 2007-04-03 2008-11-27 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough suppression, and central nervous system disorders
DE102007040615A1 (de) * 2007-08-27 2009-03-05 Bitop Ag Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
DE102007052380A1 (de) * 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
KR101654549B1 (ko) 2008-02-26 2016-09-07 패리온 사이언스 인코퍼레이티드 다중방향족 나트륨 채널 차단제
WO2009126695A2 (en) * 2008-04-08 2009-10-15 Dynamis Therapeutics, Inc. Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes
US20100074881A1 (en) * 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
ES2633177T3 (es) 2011-06-27 2017-09-19 Parion Sciences, Inc. Dipéptido química y metabólicamente estable que presenta una potente actividad bloqueadora de los canales de sodio
EA032734B1 (ru) 2012-05-29 2019-07-31 Парион Сайэнс, Инк. Дендримероподобные аминоамиды, обладающие активностью блокаторов натриевых каналов, для лечения сухости глаз и других заболеваний слизистых оболочек
WO2014036445A2 (en) * 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
CA2894279A1 (en) * 2012-12-07 2014-06-12 Paul Boucher Nasal cannula for delivery of aerosolized medicaments
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
US9029382B2 (en) * 2012-12-17 2015-05-12 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
ES2674665T3 (es) * 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
EP3035923B1 (en) 2013-08-23 2019-09-25 Parion Sciences, Inc. Dithiol mucolytic agents
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US20150376145A1 (en) 2014-06-30 2015-12-31 Parion Sciences, Inc. Stable sodium channel blockers
CA2974210A1 (en) 2015-01-30 2016-08-04 Parion Sciences, Inc. Novel monothiol mucolytic agents
CA2984424A1 (en) 2015-04-30 2016-11-03 Parion Sciences, Inc. Novel prodrugs of dithiol mucolytic agents
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
WO1992005779A1 (en) 1990-10-05 1992-04-16 The University Of North Carolina At Chapel Hill Method of administering amiloride
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
ATE347880T1 (de) 1998-10-20 2007-01-15 Univ North Carolina Methoden zum befeuchten der nasenschleimhaut
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
ES2304352T3 (es) 1999-07-19 2008-10-16 University Of North Carolina At Chapel Hill Compuestos farmacologicamente activos con dos principios activos unidos covalentemente (bloqueante de los canales de sodio/agonista del receptor p2y2) para el tratamiento de superficies mucosas.
WO2001055390A1 (en) * 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US7317013B2 (en) 2003-08-18 2008-01-08 Parion Sciences, Inc. Cyclic pyrazinoylguanidine sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
KR20060060027A (ko) 2003-08-18 2006-06-02 패리온 사이언스 인코퍼레이티드 캡핑된 피라지노일구아니딘 나트륨 채널 차단제
WO2005025496A2 (en) 2003-08-18 2005-03-24 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
AR062742A1 (es) * 2006-09-07 2008-12-03 Johnson Michael R Hidratacion de la mucosa y depuracion de la mucosa aumentadas por tratamiento con bloquadores de canales de sodio y osmolitos

Also Published As

Publication number Publication date
JP2010502738A (ja) 2010-01-28
US20080090841A1 (en) 2008-04-17
WO2008031028A3 (en) 2008-11-13
KR20090065508A (ko) 2009-06-22
CA2663041A1 (en) 2008-03-13
EP2059237A4 (en) 2010-06-30
US8058278B2 (en) 2011-11-15
TW200817343A (en) 2008-04-16
AU2007294547A1 (en) 2008-03-13
AU2007294547A2 (en) 2009-03-19
BRPI0716884A2 (pt) 2013-10-15
WO2008031028A2 (en) 2008-03-13
EP2059237A2 (en) 2009-05-20
EA200970258A1 (ru) 2009-08-28
MX2009002602A (es) 2009-05-28

Similar Documents

Publication Publication Date Title
AR062741A1 (es) Metodo para aumentar la hidratacion de la mucosa y la evacuacion de l a mucosa mediante tratamiento con bloquadores de los canales del sodio y osmolitos
AR070527A1 (es) Bloqueadores poliaromaticos del canal de sodio
AR062742A1 (es) Hidratacion de la mucosa y depuracion de la mucosa aumentadas por tratamiento con bloquadores de canales de sodio y osmolitos
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
PE20060977A1 (es) Derivados de piperidinilo como bloqueantes de canales de calcio
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
ECSP055867A (es) Derivados de pirrolopirimidina
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
PE20060837A1 (es) COMPUESTOS DE 3H-OXAZOLO Y 3H-TIAZOLO[4,5-d]PIRIMIDIN-2-ONA 3,5-DISUSTITUIDA Y 3,5,7-TRISUSTITUIDA Y PROFARMACOS DE LOS MISMOS
AR049170A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20091096A1 (es) Compuestos organicos
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
EA200801054A1 (ru) Производные пролинамида в качестве модуляторов натриевых каналов
MY184433A (en) 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
UY28700A1 (es) Compuestos
CY1114354T1 (el) Νεα παραγωγα βενζαμιδιου ως ανταγωνιστες βραδυκινινης
AR071833A1 (es) Inhibidores de quinasas (limk2), composiciones que los comprenden y metodos para tratar o prevenir enfermedades
MX2012002149A (es) Compuestos que contienen nitrogeno y composiciones farmaceuticas de los mismos para el tratamiento de fibrilacion auricular.
RU2014133390A (ru) Производные изохинолина и нафтиридина
BRPI0409230A (pt) formas de dosagem compreendendo ag013736
RU2015122032A (ru) Оксазолидинонсодержащие соединения, композиции и способы их использования

Legal Events

Date Code Title Description
FB Suspension of granting procedure